RSS feed (help and list of feeds)
Annual Review
Our new information sheets, referred to in our 2008 Annual Review, are available here.
- Annual Review 2008 - Part 1 (16 pages, 1602 KB) 21 Aug 2009
- Annual Review 2008 - Part 2 (8 pages, 2279 KB) 21 Aug 2009
- Annual Review 2008 - Part 3 (9 pages, 2435 KB) 21 Aug 2009
- Annual Review 2007 (32 pages, 2762 KB) 21 Nov 2007
- Annual Review 2007 - Part 1 (11 pages, 476 KB) 21 Nov 2007
- Annual Review 2007 - Part 2 (6 pages, 933 KB) 21 Nov 2007
- Annual Review 2007 - Part 3 (5 pages, 1092 KB) 21 Nov 2007
- Annual Review 2007 - Part 4 (10 pages, 531 KB) 21 Nov 2007
- Annual Review 2006 (32 pages, 7116 KB) 24 Nov 2006
- Annual Review 2005 (28 pages, 6467 KB) 10 Nov 2005
- Annual Review 2004 (28 pages, 1445 KB) 28 Oct 2004
- Annual Review 2003 (32 pages, 887 KB) 11 Nov 2003
- Annual Review 2002 (28 pages, 1059 KB) 04 Nov 2002
- Annual Review 2001 (31 pages, 944 KB) 01 Oct 2001
- Annual Review 2000 (31 pages, 1176 KB) 17 Oct 2000
- Annual Review 1999 (31 pages, 746 KB) 14 Dec 1999
- Annual Review 1997 (26 pages, 987 KB) 02 Oct 1998
- Annual Review 1998 (29 pages, 1209 KB) 02 Oct 1998
Page updated on 21 Aug 2009
Linked documents
Annual Review 2008 - Part 1 (16 pages, 1602 KB)
Level 9, Cigna House, 40 Mercer Street, PO Box 10-254, Wellington 6143, New Zealand Phone 64-4-460-4990 Fax 64-4-460-4995 17 December 2008 www.pharmac.govt.nz 2008 Annual Review I am pleased to provide a copy of our 2008 Annual Review, and newly-published Information…
Annual Review 2008 - Part 2 (8 pages, 2279 KB)
15 Pharmaceutical spending – getting more for less New Zealanders like to compare themselves to people in other countries, and it’s no different with pharmaceuticals. But international comparisons are difficult to make because there are differences between countries that make…
Annual Review 2008 - Part 3 (9 pages, 2435 KB)
23 Heart disease As outlined on Page 21, PHARMAC maintained full funding for the beta blocker metoprolol, at an additional cost of approximately $4 million. One of the potential funding opportunities this impacted on was a proposal to widen access…
Annual Review 2007 - Part 3 (5 pages, 1092 KB)
18 HIV/AIDS Improving New Zealanders’ access to HIV treatments was a major theme in 2006-07. Five new treatments were added to the Pharmaceutical Schedule, including the first of a new type of HIV medicine, a fusion inhibitor. The five new…
Annual Review 2006 (32 pages, 7116 KB)
PHARMAC invested in health by providing new or expanded access to 41 subsidised treatments New investments include treatments for cardiovascular risk, schizophrenia, rheumatoid arthritis, osteoporosis, hepatitis, Parkinson’s disease, multiple…
Annual Review 2002 (28 pages, 1059 KB)
Major PHARMAC achievements in 2001-02 were: Providing new or wider access to 24 subsidised treatments, including those for raised cholesterol, multiple sclerosis, schizophrenia, epilepsy, arthritis and hay fever under cost-neutral and/or financially sustainable arrangements. Containing pharmaceutical expenditure growth by successfully negotiating savings worth approximately $36.8 million...
Annual Review 1999 (31 pages, 746 KB)
R Annual evıew for the year ended 30 June 1999 P H A R M AC (the Pharmaceutical Management Agency Ltd) is a not-for-profit company owned by the Health Funding Authority (HFA). Its role is to manage the national Pharmaceutical…
